Palliation of hepatic tumors

Cunningham, Steven C.; Choti, Michael A.; Bellavance, Emily; Pawlik, Timothy M.

doi:10.1016/j.suronc.2007.08.010

Cited by 48 publications

(41 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased use of imaging has improved the detection of liver metastases. Twenty percent of colorectal cancer patients have liver metastases at diagnosis, and most colorectal cancer deaths are attributed to metastases (Chung et al, 2005 et al;Cunningham et al, 2007;Lee et al, 2008) . Metastasectomy can achieve a promising survival rate.…”

Section: Introductionmentioning

confidence: 99%

Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Yin

Lü²,

Qiao³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The purpose of this study was to investigate whether whole-liver radiotherapy plus a tumor-boost dose with concurrent chemotherapy is beneficial for colorectal cancer patients with massive and multiple liver metastases. There were only two cases of Grade 3 toxicity (elevated bilirubin). These data provide evidence that whole-liver radiotherapy plus a tumor-boost dose with concurrent chemotherapy is beneficial for colorectal cancer patients with massive and multiple liver metastases.

show abstract

Section: Introductionmentioning

confidence: 99%

Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Yin

Lü²,

Qiao³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Currently, only a small percentage of patients are candidates for curative treatments, due to underlying liver disease, extent of metastasis, and limited availability of livers for transplantation 6. The remaining majority of patients are eligible only for palliative treatments, which result in modest prolongation of survival7, 8. HCC is therefore an aggressive disease, characterized by poor prognosis and limited treatment options, highlighting the critical need for the development of novel and effective therapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells

Altomonte

Meseck

et al. 2008

Cancer Gene Ther

View full text Add to dashboard Cite

Recombinant oncolytic viruses represent a promising alternative option for the treatment of malignant cancers. We have reported earlier the safety and efficacy of recombinant vesicular stomatitis virus (VSV) vectors in a rat model of hepatocellular carcinoma (HCC). However, the full potential of VSV therapy is limited by a sudden decline in intratumoral virus replication observed early after viral administration, a phenomenon that coincides with an accumulation of inflammatory cells within infected lesions. To overcome the antiviral function of these cells, we present a recombinant virus, rVSV-UL141, which expresses a protein from human cytomegalovirus known to downregulate the natural killer (NK) cell-activating ligand CD155. The modified vector resulted in an inhibition of NK cell recruitment in vitro, as well as decreased intratumoral accumulations of NK and NKT cells in vivo. Administration of rVSV-UL141 through hepatic artery infusion in immune-competent Buffalo rats harboring orthotopic, multi-focal HCC lesions resulted in a one-log elevation of intratumoral virus replication over a control rVSV vector, which translated to enhance tumor necrosis and substantial prolongation of survival. Moreover, these results were achieved in the absence of apparent toxicities. The present study suggests the applicability of this strategy for the development of effective and safe oncolytic agents to treat multi-focal HCC, and potentially a multitude of other cancers, in the future.

show abstract

“…Palliative procedures included biliary bypass and cholecystectomy, both of which have been previously reported as palliative procedures to help improve quality of life. 9–11 Perioperative morbidity was classified according to the Clavien-Dindo classification system while other short-term perioperative outcomes recorded for each patient included index hospitalization length of stay (LOS), perioperative mortality, and 30-day readmission. 12 Overall survival (OS) was calculated from the date of surgery to the date of death or last follow-up, as appropriate.…”

Section: Methodsmentioning

confidence: 99%

Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study

Buettner

Wilson

Margonis

et al. 2016

Journal of Gastrointestinal Surgery

Self Cite

View full text Add to dashboard Cite

Introduction Extrahepatic biliary malignancies are often diagnosed at an advanced stage. We compared patients with unresectable perihilar cholangiocarcinoma (PHCC) and gallbladder cancer (GBC) who underwent a palliative procedure versus an aborted laparotomy. Methods Seven hundred seventy-seven patients who underwent surgery for PHCC or GBC between 2000 and 2014 were identified. Uni- and multivariable analyses were performed to identify factors associated with outcome. Results Utilization of preoperative imaging increased over time (CT use, 80.1 % pre-2009 vs. 90 % post-2009) (p <0.001). The proportion of the patients undergoing curative-intent resection also increased (2000–2004, 67.0 % vs. 2005–2009, 74.5 % vs. 2010–2014, 78.8 %; p =0.001). The planned surgery was aborted in 106 (13.7 %) patients and 94 (12.1 %) had a palliative procedure. A higher incidence of postoperative complications (19.2 vs. 3.8 %, p =0.001) including deep surgical site infections (8.3 vs. 1.1 %), bleeding (4.8 vs. 0 %), bile leak (6.0 vs. 0 %) and longer length of stay (7 vs. 4.5 days) were observed among the patients who underwent a palliative surgical procedure versus an aborted non-therapeutic, non-palliative laparotomy (all p <0.05). OS was comparable among the patients who underwent a palliative procedure (8.7 months) versus an aborted laparotomy (7.8 months) (p =0.23). Conclusion Increased use of advanced imaging modalities was accompanied by increased curative-intent surgery. Compared with patients in whom surgery was aborted, patients who underwent surgical palliation demonstrated an increased incidence of postoperative morbidity with comparable survival.

show abstract

Palliation of hepatic tumors

Cited by 48 publications

References 155 publications

Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells

Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study

Contact Info

Product

Resources

About